冠心病患者 PCI 后的抗血小板药物治疗

月清 刘(内蒙古医科大学内蒙古自治区人民医院，中国;)
璐莎 鄂(内蒙古自治区人民医院，中国;)

摘要

抗血小板药物治疗在冠状动脉粥样硬化性心脏病（coronary artery disease，CAD）简称冠心病患者的经皮冠状动脉介入治疗（percutaneous coronary intervention，PCI）后不可或缺。研究显示，抗血小板药物的治疗方案与冠心病患者PCI后的预后密切相关，合理的用药方案往往能显著提高患者的生存率和生活质量。笔者总结了目前冠心病PCI后临床常用抗血小板药物的治疗进展，并着重对有关氯吡格雷的基因检测在抗血小板药物治疗中的应用现状进行综述，为冠心病患者PCI后的抗血小板药物治疗提供更加科学、合理的思路，从而更好地改善冠心病患者的预后。

关键词

冠心病；PCI；抗血小板治疗；基因检测

参考

HAHN J Y, SONG Y B, OH J H, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial[J]. Jama, 2019, 321(24):2428-37.

李明艳,史威力,段红艳.阿司匹林用于成年人心血管疾病的一级预防:美国预防临床服务指南工作组推荐声明解读[J].中国全科医学,2024,27(11):1277-1282.

徐利明,王子华.氯吡格雷对冠心病心力衰竭患者血小板、凝血功能、心功能指标的影响[J].血栓与止血学,2022,28(3):592-593.

TAO L, REN S, ZHANG L, et al. A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases[J]. Medical science monitor : international medical journal of experimental and clinical research, 2022.

JAMES S K, ROE M T, CANNON C P, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial[J]. BMJ (Clinical research ed), 2011.

JAMES S, AKERBLOM A, CANNON C P, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial[J]. American heart journal, 2009, 157(4): 599-605.

WANG Y, JIANG Y, ZHI W, et al. Safety and feasibility of low-dose ticagrelor in patients with ST-segment elevation myocardial infarction[J]. Clinical cardiology, 2021,44(1):123-128.

王悦,刘倍倍,陈蕾蕾,等.急性冠状动脉综合征患者经皮冠状动脉介入治疗术后接受小剂量替格瑞洛疗效的性别差异研究[J].中国介入心脏病学杂志,2021,29(6):337-341.

BISWAS M, SUKASEM C, KHATUN KALI M S, et al. Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis[J]. Pharmacogenomics, 2022, 23(3):207-220.

LEE C R, LUZUM J A, SANGKUHL K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update[J]. Clinical pharmacology and therapeutics, 2022,112(5):959-967.[11 ] CHEN Y W, LIAO Y J, CHANG W C, et al. CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel[J]. Front Cardiovasc Med, 2022.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i12.22870